West Pharmaceutical Services (WST) faces mixed market results. Following the release of
lower-than-expected results and a
reduced future guidance, the company's stock took a hit. Regardless, numerous financial organizations maintain significant stock positions in WST, including the
New York State Teachers Retirement System and
International Assets Investment Management LLC. Following Q3 reporting, West topped
earnings and revenue estimates which resulted in an
EPS beat of 27%. Furthermore, Q3 2024
Earnings Call Highlights noted strong performance and raised annual forecasts due to increased demand for medical supplies. However, the company's Q4 earnings have been negatively estimated by William Blair. Despite industry headwinds causing a dip in the stock, West Pharmaceutical maintains its position as one of the
safest dividend aristocrats for 2024. The company is seeing rising demand for syringes, prompting increased annual forecasts and dividends. Lastly, WST continues to be a strong investment choice, with several asset management companies like
Hennion & Walsh and
Raymond James & Associates increasing their holding in the company.
West Pharmaceutical Services WST News Analytics from Thu, 16 Feb 2023 08:00:00 GMT to Sat, 02 Nov 2024 08:44:12 GMT -
Rating 5
- Innovation 4
- Information 6
- Rumor 3
